EI
ATXS

EAM Investors’s Astria Therapeutics ATXS Stock Holding History

EAM Investors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-72,129
Closed -$959K – 272
2023
Q1 		$959K Sell
72,129
-19,216
-21% -$260K 0.19% 232
2022
Q4 		$1.36M Buy
+91,345
New +$942K 0.28% 166

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EAM Investors's ATXS Position: Q2 2023 in Review

EAM Investors sold out of Astria Therapeutics (ATXS) in Q2 2023, closing a stake of 72,129 shares — an estimated $959K sold.

EAM Investors first reported a position in ATXS in Q4 2022 and held it in 2 quarters. The position peaked at $1.36M in Q4 2022. 76 funds tracked by Wall St. Rank hold ATXS as of Q2 2023.

  • EAM Investors reported no remaining Astria Therapeutics position as of Q2 2023 after selling out during the quarter.
  • EAM Investors sold 72,129 Astria Therapeutics shares in Q2 2023, an estimated $959K.
  • EAM Investors first reported a position in Astria Therapeutics in Q4 2022 and held it in 2 quarters.
  • EAM Investors's Astria Therapeutics position peaked at $1.36M in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.